We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,030

Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Global Privacy & Cybersecurity Update Vol. 15
  • Jones Day
  • USA, European Union, Global
  • September 13 2017

On June 19, the Federal Trade Commission ("FTC") submitted comments to a working group organized by the Department of Commerce's National


Dietary Supplement & Cosmetics Legal Bulletin: March 2017
  • Shook Hardy & Bacon LLP
  • USA
  • March 31 2017

FDA Warning Letters on the Rise. Nearly 30 warning letters were issued by the U.S. Food and Drug Administration (FDA) regarding


Prime Therapeutics Notice of Audit or Termination of Agreement - What You Need to Know
  • FisherBroyles LLP
  • USA
  • January 30 2017

It has come to our attention that Prime Therapeutics (Prime), a Pharmacy Benefit Manager (PBM) that maintains contractual agreements with many


Regulatory Concerns Around Big Data, Artificial Intelligence and the IoT
  • Manatt Phelps & Phillips LLP
  • USA
  • January 23 2017

Data is everywhere. By some estimates, 90 of the world's data has been created in the last two years. This deluge is only going to intensify as the


"Key Takeaways: Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies"
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • October 24 2016

On October 5, 2016, Skadden hosted its Fourth Annual Seminar for Pharmaceutical, Biotechnology and Medical Device Companies. The seminar focused on


Advertising Litigation Report: Vol. I, No. 3
  • Kramer Levin Naftalis & Frankel LLP
  • USA
  • August 9 2016

In a dispute between rival pharmaceutical manufacturers, the Second Circuit affirmed summary judgment for defendant Acorda Therapeutics, adopting the


Financial Reporting: 2016 Mid-Year Update
  • Jones Day
  • USA
  • July 14 2016

We are pleased to offer our clients and friends this mid-year update on financial reporting and issuer disclosure enforcement activity in 2016. The


Final Food Safety Modernization Act Rule: Intentional Adulteration
  • Squire Patton Boggs
  • USA
  • June 13 2016

The seventh and final component of the FDA Food Safety Modernization Act was finalized and published on May 27, 2016. The Intentional Adulteration


Disregard of Speculative Financial Projections Was Not Bad Faith
  • Morris James LLP
  • USA
  • June 1 2016

In a stockholder challenge to a sale of the company, a plaintiff may rebut the business judgment rule by pleading facts that support a reasonable